Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Recent & Breaking News (NDAQ:ACAD)

ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire May 24, 2023

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

Business Wire May 8, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 5, 2023

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire May 2, 2023

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

Business Wire April 25, 2023

Acadia Pharmaceuticals to Present DAYBUE(TM) (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

Business Wire April 20, 2023

Acadia Pharmaceuticals Announces DAYBUE(TM) (trofinetide) is Now Available for the Treatment of Rett Syndrome

Business Wire April 17, 2023

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Business Wire April 11, 2023

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE(TM) (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

Business Wire March 10, 2023

ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

Business Wire March 3, 2023

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

Business Wire February 27, 2023

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

Business Wire February 14, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 13, 2023

Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development

Business Wire January 9, 2023

Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson's Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics

Business Wire January 3, 2023

Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

Business Wire December 21, 2022

ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

Business Wire November 25, 2022

ACADIA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

PR Newswire November 11, 2022

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire November 8, 2022

Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results

Business Wire November 2, 2022